Company Overview
OrthoPediatrics Corp. operates as a medical device company dedicated to designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces specifically for children suffering from orthopedic conditions in both the United States and international markets. The company functions within the Healthcare sector and the Medical Devices industry, a domain characterized by high regulatory standards and specialized product requirements that demand significant research and development investment to meet specific pediatric anatomical needs. The enterprise currently maintains a market capitalization of $410.27M and employs a workforce of 602 individuals, generating annual revenue of $236.35M. These financial figures indicate that while the company has established a substantial operational footprint with over $236 million in revenue, its market valuation suggests it is currently valued as a mid-cap entity rather than a large-cap leader, reflecting the capital-intensive nature of its development and sales model within a niche pediatric orthopedic market.
Financial Health
The company reported revenue of $236.35M for the trailing twelve months, yet it posted a net income of $-39,648,000 and an EBITDA of $-7,880,000, revealing a significant gap where operating expenses substantially exceed gross profit before tax and interest considerations. This disparity between positive revenue and negative net income and EBITDA highlights a cost structure where research, development, and selling costs are high relative to the margins generated on product sales. Free cash flow stands at $-10,020,875, indicating that the company is currently burning cash through its operations and capital expenditures, which limits its immediate financial flexibility for organic expansion or acquisitions without external financing. The company's profitability metrics show a gross margin of 73.1%, which indicates strong pricing power or high manufacturing efficiency on the products sold, yet this is offset by an operating margin of -8.9% and a profit margin of -16.8%, demonstrating that overhead costs and other expenses are eroding the majority of the gross profit. On the balance sheet, the company holds $60.85M in cash against $111.98M in debt, resulting in a debt-to-equity ratio of 32.31, which suggests a leveraged position where liabilities exceed equity significantly. Despite the high debt load, the current ratio of 5.55 indicates a robust ability to meet short-term obligations with current assets, providing a buffer against immediate liquidity crises. Return on Equity is recorded at -11.3% and Return on Assets at -3.7%, metrics that reveal the company is currently generating negative returns on its capital base, reflecting the challenges of sustaining profitability while scaling operations in a competitive medical device landscape.
Valuation Assessment
Valuation multiples for OrthoPediatrics Corp. present a mixed picture, with a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is calculated at -23.35, implying that the market is pricing in future earnings recovery or that traditional earnings-based valuation is not currently applicable. The price-to-book ratio sits at 1.18, suggesting that the company trades at a slight premium over its book value, which can indicate market confidence in the intangible assets or future growth potential despite current losses. Alternative valuation metrics provide further context, with a price-to-sales ratio of 1.74 and an EV/EBITDA of -58.55, figures that suggest the market is valuing the company primarily on its revenue generation capabilities rather than current profitability. The stock's trading range over the past year spans a 52-week high of $26.40 and a 52-week low of $15.28, placing the current valuation context within this historical band to assess relative price positioning. The beta value of 1.11 indicates that the stock's price volatility is slightly higher than that of the broader market, meaning the stock is expected to move 11% more than the market index in response to general market fluctuations.
Growth & Income
OrthoPediatrics Corp. demonstrated revenue growth of 17.0% year-over-year, while earnings growth is N/A due to the company's current unprofitable status, indicating that top-line expansion is occurring independently of immediate bottom-line improvements. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all available earnings back into the business rather than distributing cash to shareholders. This lack of a dividend payout is consistent with the company's need to fund its own growth initiatives and manage its cash burn rate rather than providing regular income to investors. Overall, the company's profile is defined by strong revenue expansion in a specialized niche, though the absence of earnings growth and dividends reflects the early-stage financial characteristics of a company focused on market penetration and product development in the pediatric orthopedic sector.